InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Friday, 04/29/2016 9:56:10 PM

Friday, April 29, 2016 9:56:10 PM

Post# of 48316
Radiation + ipilimumab combo

Attempting to mirror his treatment experience, the researchers recruited 22 previously treated and untreated stage IV melanoma patients for a phase I clinical trial that investigated the use of both modalities. The group received stereotactic body radiation therapy (SBRT) to a single tumor followed three to five days later with ipilimumab every three weeks for four cycles.

The team found that 18 percent of patients had partial response in unirradiated tumors, 18 percent had stable disease and 64 percent had progressive disease. The median progression free survival and overall survival for patients was 3.8 months and 10.7 months with a median follow up of 18.4 and 21.3 months, respectively. The group’s overall survival rate was 35 percent. A past, phase III study showed an overall survival rate of 20 percent in patients on ipilimumab alone.

http://www.uphs.upenn.edu/news/News_Releases/2015/03/minn/